Doseology Completes Strategic Acquisition
Doseology Sciences Inc. (CSE: MOOD, OTC: DOSEF, FSE: VU) is thrilled to announce an important milestone in its mission to be a leader in precision-formulated oral stimulants. The company has successfully closed the acquisition of the "Feed That Brain" division from Joseph Mimran & Associates Inc., marking a significant advancement for Doseology.
Details of the Acquisition
As part of the acquisition agreement, Doseology has issued 175,000 common shares at a deemed price of $1.00 per share. This transaction fulfills the first payment required under the asset purchase and sale agreement between Doseology and the Vendor. The shares distributed to the Vendor will be subject to a four-month hold period, in compliance with existing Canadian securities laws.
Expanding Product Offerings
This acquisition allows Doseology to bolster its product portfolio, particularly in the realm of cognitive enhancement and stimulation. The "Feed That Brain" product line is known for harnessing unique ingredients aimed at improving energy, focus, and overall cognitive performance. By integrating this division, Doseology will be positioned to offer enhanced solutions to its customers.
Innovation in Cognitive Performance
At Doseology, innovation is at the forefront of its operations. The company focuses on developing advanced oral stimulant formulas backed by rigorous scientific research. The newly acquired products align perfectly with Doseology's existing mission to create next-generation performance solutions that empower individuals to achieve peak cognitive abilities.
Leadership Vision
"We are excited to welcome the Feed That Brain team into the Doseology family," said Chris Jackson, CEO of Doseology Sciences Inc. "This acquisition is a strategic move that enhances our capabilities and offerings in cognitive enhancement products, enabling us to serve our clients better and drive further innovation in the industry."
Commitment to Excellence
Doseology's commitment to developing premium-quality cognitive products remains unwavering. With this acquisition, the company plans to leverage existing technologies and research to enhance product formulations that support mental acuity and overall cognitive health.
Looking to the Future
As Doseology Sciences Inc. continues to expand its reach through strategic acquisitions, the focus remains on delivering exceptional products that meet the high standards of consumers. The integration of the Feed That Brain division is expected to provide new avenues for growth and advancement in the rapidly evolving biotech industry.
Contact Information
For more information, interested parties can reach out to Doseology Sciences Inc. via the following channels:
Email: hello@doseology.com
Website: www.doseology.com
Phone: 604.908.3095
Frequently Asked Questions
1. What does the acquisition of Feed That Brain entail?
The acquisition grants Doseology access to the Feed That Brain product line, enhancing its offerings in cognitive performance.
2. How many shares were issued to the Vendor?
The transaction involved the issuance of 175,000 common shares at a price of $1.00 per share.
3. What will be the hold period for the shares?
The issued shares will have a four-month hold period per Canadian securities regulations.
4. Who is leading Doseology Sciences Inc.?
Chris Jackson serves as the CEO of Doseology, driving the company's strategic vision.
5. How can I learn more about Doseology's projects?
For more information, individuals can visit the official Doseology website or contact the company directly via email.
